Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,115 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: genetic analysis Clear all
Terminated Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

NCT00450983
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 25, 2026, 7:34 PM EDT
Recruiting Not applicable Interventional

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

NCT06630104
View directory record Official record
Conditions
Lymphoproliferative Disorder, Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Recruiting No phase listed Observational

Molecular Genetics of Heterotaxy and Related Congenital Heart Defects

NCT02432079
View directory record Official record
Conditions
Heterotaxy Syndrome, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Cetuximab in Treating Patients With Advanced Solid Tumors

NCT00376727
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Oct 25, 2026, 7:34 PM EDT
Active, not recruiting Not applicable Interventional

To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That Develop to the Point That They Are Able to be Transferred) in IVF Cycles.

NCT07369362
View directory record Official record
Conditions
Infertility, Male Infertility, InVitro Fertilization, Aneuploidy Rate, Euploidy Rate
Interventions
microfludics semen processing device
Device
Lead sponsor
MotilityCount aps
Industry
Eligibility
21 Years to 45 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Completed No phase listed Observational

Multi-center Study to Validate niPGT-A

NCT03520933
View directory record Official record
Conditions
Aneuploidy, Chromosome Abnormality, Infertility
Interventions
PGT-A, niPGT-A
Diagnostic Test
Lead sponsor
Igenomix
Industry
Eligibility
20 Years to 44 Years · Female only
Enrollment
2,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • Arlington, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 25, 2026, 7:34 PM EDT
Completed No phase listed Observational

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

NCT01284010
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 25, 2026, 7:34 PM EDT
Not listed No phase listed Observational

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

NCT00900224
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT01673217
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
Drug · Biological · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 25, 2026, 7:34 PM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 25, 2026, 7:34 PM EDT
Not listed Not applicable Interventional

Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care

NCT04685304
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic Testing, Pharmacist Consultation Note, Delayed pharmacogenetic testing
Genetic · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 25, 2026, 7:34 PM EDT
Suspended No phase listed Observational

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

NCT04955808
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Completed No phase listed Observational Results available

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

NCT01494298
View directory record Official record
Conditions
Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
Interventions
Not listed
Lead sponsor
Mercer University
Other
Eligibility
18 Years to 79 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 25, 2026, 7:34 PM EDT
Completed No phase listed Observational

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

NCT00010114
View directory record Official record
Conditions
Central Nervous System Embryonal Neoplasm
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 2 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

NCT01196247
View directory record Official record
Conditions
Previously Treated Metastatic Pancreatic Cancer
Interventions
Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank
Drug
Lead sponsor
Translational Drug Development
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 25, 2026, 7:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

NCT06927947
View directory record Official record
Conditions
Hereditary Malignant Neoplasm, Hereditary Neoplastic Syndrome
Interventions
Communication Intervention, Health Promotion and Education, Informational Intervention, Survey Administration
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 7:34 PM EDT
Not listed No phase listed Observational

Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens

NCT02749838
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Pharmatech
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 25, 2026, 7:34 PM EDT
Not listed No phase listed Observational

Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting

NCT05053815
View directory record Official record
Conditions
Pharmacogenomics, Polypharmacy
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 25, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

NCT00611715
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, letrozole, fluorescence in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 25, 2026, 7:34 PM EDT
Withdrawn No phase listed Observational

Research Study in Patients With Advanced Ovarian Epithelial Cancer

NCT00053235
View directory record Official record
Conditions
Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Comparative Genomic Hybridization, Laboratory Biomarker Analysis, Polymerase Chain Reaction
Genetic · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 25, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00633750
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 25, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional

Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00323791
View directory record Official record
Conditions
Kidney Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 25, 2026, 7:34 PM EDT
Completed No phase listed Observational

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

NCT02790944
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Multi-gene Next Generation Sequencing Panel
Genetic
Lead sponsor
Ambry Genetics
Industry
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 25, 2026, 7:34 PM EDT